CSPC Pharmaceutical Group Limited (CSPCY)
USD 3.05
(-2.71%)
USD 3.05
(-2.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.53 Billion CNY | -1.24% |
| 2022 | 8.65 Billion CNY | 12.03% |
| 2021 | 7.72 Billion CNY | 11.69% |
| 2020 | 7.21 Billion CNY | 28.58% |
| 2019 | 5.35 Billion CNY | 34.54% |
| 2018 | 4.49 Billion HKD | 37.71% |
| 2017 | 3.51 Billion HKD | 22.95% |
| 2016 | 2.92 Billion HKD | 33.7% |
| 2015 | 1.75 Billion HKD | 36.81% |
| 2014 | 1.28 Billion HKD | 33.47% |
| 2013 | 961.97 Million HKD | -47.93% |
| 2012 | 2.05 Billion HKD | 668.32% |
| 2011 | 240.43 Million HKD | -70.04% |
| 2010 | 802.49 Million HKD | -18.15% |
| 2009 | 980.39 Million HKD | 1.08% |
| 2008 | 969.91 Million HKD | 97.13% |
| 2007 | 492.01 Million HKD | 30568.23% |
| 2006 | 1.6 Million HKD | -98.97% |
| 2005 | 155.09 Million HKD | -41.4% |
| 2004 | 264.64 Million HKD | -58.48% |
| 2003 | 637.34 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.26 Billion CNY | 26.54% |
| 2024 Q2 | 1.94 Billion CNY | 0.0% |
| 2023 Q4 | 1.78 Billion CNY | -7.53% |
| 2023 Q2 | 1.9 Billion CNY | 6.81% |
| 2023 Q1 | 1.78 Billion CNY | -8.3% |
| 2023 FY | - CNY | -1.24% |
| 2023 Q3 | 1.93 Billion CNY | 1.44% |
| 2022 Q3 | 1.88 Billion CNY | -4.05% |
| 2022 FY | - CNY | 12.03% |
| 2022 Q1 | 1.76 Billion CNY | -20.4% |
| 2022 Q2 | 1.96 Billion CNY | 11.07% |
| 2022 Q4 | 1.94 Billion CNY | 3.41% |
| 2021 Q4 | 2.21 Billion CNY | 8.31% |
| 2021 FY | - CNY | 11.69% |
| 2021 Q3 | 2.04 Billion CNY | 5.22% |
| 2021 Q1 | 2.16 Billion CNY | 18.85% |
| 2021 Q2 | 1.94 Billion CNY | -10.14% |
| 2020 Q1 | 1.4 Billion CNY | 3.62% |
| 2020 Q4 | 1.82 Billion CNY | -6.41% |
| 2020 FY | - CNY | 28.58% |
| 2020 Q3 | 1.94 Billion CNY | 12.1% |
| 2020 Q2 | 1.73 Billion CNY | 23.79% |
| 2019 Q1 | 1.5 Billion CNY | 32.37% |
| 2019 Q3 | 1.39 Billion CNY | -4.29% |
| 2019 Q4 | 1.35 Billion CNY | -3.12% |
| 2019 FY | - CNY | 34.54% |
| 2019 Q2 | 1.46 Billion CNY | -2.61% |
| 2018 Q1 | 1.31 Billion CNY | 23.06% |
| 2018 Q2 | 1.26 Billion CNY | -3.68% |
| 2018 Q3 | 1.2 Billion CNY | -5.1% |
| 2018 Q4 | 1.13 Billion CNY | -5.72% |
| 2018 FY | - HKD | 37.71% |
| 2017 FY | - HKD | 22.95% |
| 2017 Q4 | 1.06 Billion CNY | 1.14% |
| 2017 Q3 | 1.05 Billion CNY | 4.4% |
| 2017 Q2 | 1.01 Billion CNY | 6.91% |
| 2017 Q1 | 946.84 Million CNY | 16.72% |
| 2016 Q3 | 821.59 Million CNY | 1.2% |
| 2016 Q4 | 811.22 Million CNY | -1.26% |
| 2016 Q2 | 811.87 Million CNY | 3.77% |
| 2016 FY | - HKD | 33.7% |
| 2016 Q1 | 782.37 Million CNY | 12.14% |
| 2015 Q4 | 697.68 Million CNY | 0.57% |
| 2015 FY | - HKD | 36.81% |
| 2015 Q3 | 693.7 Million CNY | -1.38% |
| 2015 Q2 | 703.38 Million CNY | 5.99% |
| 2015 Q1 | 663.64 Million CNY | 12.5% |
| 2014 Q4 | 589.91 Million CNY | 0.47% |
| 2014 FY | - HKD | 33.47% |
| 2014 Q1 | 517.86 Million CNY | 7.37% |
| 2014 Q2 | 591.13 Million CNY | 14.15% |
| 2014 Q3 | 587.14 Million CNY | -0.67% |
| 2013 Q4 | 482.32 Million CNY | 44.97% |
| 2013 FY | - HKD | -47.93% |
| 2013 Q3 | 332.69 Million CNY | -24.35% |
| 2013 Q2 | 439.8 Million CNY | 19.71% |
| 2013 Q1 | 367.38 Million CNY | 0.0% |
| 2012 FY | - HKD | 668.32% |
| 2011 FY | - HKD | -70.04% |
| 2010 FY | - HKD | -18.15% |
| 2009 FY | - HKD | 1.08% |
| 2008 FY | - HKD | 97.13% |
| 2007 FY | - HKD | 30568.23% |
| 2006 FY | - HKD | -98.97% |
| 2005 FY | - HKD | -41.4% |
| 2004 FY | - HKD | -58.48% |
| 2003 FY | - HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | 35.794% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 56.055% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -643.229% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 21590.387% |
| Novartis AG | 19.51 Billion USD | 56.282% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -2861.389% |